The collaboration will leverage microRNAs’s significant potential as highly sensitive and specific biomarkers, to develop a wide range of diagnostic and prognostic tests. This is the company’s first collaboration to include a focus on diagnostics for women’s health indications.
Amir Avniel, president and CEO of Rosetta Genomics, said: “MicroRNAs’s unique characteristics as sensitive and specific biomarkers, coupled with our strong development engines, enable us to expand and advance our development programs outside the oncology field.”